New NICE guidance: people on obesity jabs “need additional help” and “keep fit” to stave off weight regain

Around 240,000 people are expected to be offered tirzepatide over the next three years (Image: pixabay.com/Michal Jarmoluk)

People who are coming off weight management injections should be offered professional help – including getting fit – to ensure they do not regain their excess weight following treatment. 

New guidance from NICE, the UK’s National Institute for Health and Care Excellence – which informs the work of the National Health Service – warns that weight management is a long-term journey, not a “short-term fix”.

Updating its quality standard for the use of obesity jabs, NICE sets out new expectations for healthcare providers. These include offering ongoing advice and tailored action plans – covering everything from regular check-ins and practical strategies to support with sustainable routines, social support and accessing community help.

Published today (5 August), the new advice outlines how people using weight management injections – such as liraglutide (Saxenda), semaglutide (Wegovy) and tirzepatide (Mounjaro) – need to build long-term behavioural habits. 

“Research shows that many people regain weight after stopping treatment if they don’t get the right help,” the new guidance states. 

“This can negatively affect both their physical and mental health.

“Healthcare teams should monitor people for at least a year after they complete treatment and offer extra support if needed. This could include practical advice  from programmes like NHS Better Health on changing daily habits or making adjustments at home or work to avoid slipping back.”

Among the measures recommended by NICE is for patients to work alongside professionals to produce an action plan that they can easily put into practice if they are not maintaining changes and other local peer support groups – such as keep fit or walking groups.

The guidance comes as new weight loss drugs are now available to those with the greatest need on the NHS. Around 240,000 people are expected to be offered tirzepatide over the next three years.

Professor Jonathan Benger, deputy chief executive and chief medical officer at NICE, said: “Successful weight management doesn’t end when medication stops or when someone completes a behavioural programme.

“We know that the transition period after treatment is crucial, and people need structured support to maintain the positive changes they’ve made.

“This new standard makes sure services provide that vital continuity of care, and it supports the NHS 10 Year Plan to shift from a ‘sickness service’ to a genuine health service focused on prevention.”

The updated standard replaces three previous standards and reflects the most up-to-date thinking on how to tackle overweight and obesity through the health system.

Dr Rebecca Payne, Chair of NICE’s Quality Standards Advisory Committee, said: “Weight management is a long-term journey, not a short-term fix. The evidence is clear that advice and support for maintaining weight after stopping medicines or completing behavioural interventions can help prevent weight regain and enable people to experience lasting benefits.

“We’ve seen excellent examples of services that already provide comprehensive discharge planning and ongoing support. This quality standard will help ensure all healthcare providers adopt these best practices, giving every person the best chance of maintaining their weight management success over the long term.

“This standard ensures healthcare services are equipped to provide that essential ongoing support.”

The updated advice is available on the NICE website.

Recommended Posts